Competitor Landscape: Atopic Dermatitis

Competitor Landscape: Atopic Dermatitis

Summary

Competitor Landscape: Atopic Dermatitis, briefings contain evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

• AT-502 is the second topical JAK inhibitor in development for atopic dermatitis behind ruxolitinib/ INCB018424, however is the only topical JAK inhibitor targeting moderate-to-severe AD.
• Upadacitinib and baricitinib are competing to the first-in-class JAK inhibitor approved for AD, with upadacitinib likely approved a quarter before baricitinib in the US.
• Data for PF-04965842's adolescent trial will likely be released in Q4 2019, and along with data from JADE Mono-1, will be the basis for filing in the adolescent patient population.

The report contains five key sections.

Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted view of the atopic dermatitis landscape.

Landscape Updates -

• ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
• Timeline forecasts for each approved product’s lifecycle management initiatives.

Pipeline Landscape -

• An overview of pipeline candidates, containing snapshots of current development status.
• Expected drug-specific events & milestones until YE 2019.

Approved Product Landscape -

• An overview of pipeline candidates, containing snapshots of current development status.
• Expected drug-specific events & milestones until YE 2019.

Appendix -

• Current early stage atopic dermatitis pipeline & candidate ‘Watch List’.
• Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

• The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
• Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
• Forecasts are presented in pipeline forecast figures & detailed tables
• ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

• Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
• Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
• Reviews ongoing lifecycle management strategies for existing players in the market
• A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.